U.S. Urges China to Help Curb Iran’s Actions in Gulf, Rubio Says 
Asian Currencies Slide as Indian Rupee Hits Record Low Amid Iran Tensions 
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia 
Nidec Shares Plunge After Quality Inspection Misconduct Allegations 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Japan Considers Extra Budget Aid Amid Rising Fuel and Utility Costs 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
New Zealand Budget 2026 Focuses on Fiscal Discipline and Infrastructure Investment 
Asian Stocks Steady as Iran War Concerns Persist Ahead of Trump-Xi Summit 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Havana Protests Erupt as Cuba Faces Severe Blackouts and Fuel Crisis 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
Trump, Xi Begin High-Stakes China Summit Focused on Trade, Taiwan and Global Tensions 
Arteris Stock Surges After Strong Q1 Earnings Beat and Higher 2026 Outlook 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Australia Housing Tax Reform Sparks Debate Over Property Investor Tax Breaks 
Pfizer announced on Wednesday, April 28, that it has acquired Amplyx Pharmaceuticals. The company stated that the purchase would bolster its portfolio as it offers the opportunity to strengthen “Pfizer’s expertise and deep heritage in infectious disease.”
As per Reuters, Amplyx Pharmaceuticals is based in San Diego, and it is developing new treatments against drug-resistant microbes in patients with compromised immune systems.
The anti-fungal drug has been named fosmanogepix, and it is now in the second phase of clinical trials.
Pfizer to continue testing on Amplyx’s experimental drug
The New York-headquartered multinational pharmaceutical company acquired Amplyx while it is in the middle of conducting trials for its anti-fungal drug that is hoped to effectively fight off drug-resistant infections that ravage the immune system of patients. Since this is the case, Pfizer will not abandon but continue the clinical trials of this experimental drug.
If Amplyx's fosmanogepix drug will show good results and eventually be approved, it will become the first type of new antifungal treatment to come in the last 20 years. This is an important drug because it can kill fungi, like bacteria, that have turned resistant to common drugs or medicines.
Why Pfizer is further expanding its infectious disease folio
It was estimated that if this kind of drug will not be developed, drug-resistant superbugs may possibly kill at least 10 million people by 2050. This is why Pfizer has been expanding its portfolio for treatments that can fight these threatening superbugs.
Pfizer noted that hospitalized patients’ immune systems tend to become weaker since the drugs they take do not work, and this has become a problem not just for the ill but for doctors as well. This scenario just showed how much people need effective anti-fungal treatments for such patients.
“The COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections,” Pfizer Hospital’s global president, Angela Lukin, said in a press release. “We are deeply committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies.”
